secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001847903-24-000079
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa Q1 net loss $38M; initiates ORX750 Phase 1, cash runway into mid-2026
------------------------------------------------------------------------------

- Net loss of $38.0M, improved from $50.7M in Q1 2023; R&D expense $22.7M vs $32.8M.
- Cash, equivalents, and short-term investments $230.2M as of March 31, plus $107.2M net from April/May ADS offering.
- Phase 1 first-in-human trial of ORX750 (narcolepsy) initiated; proof-of-concept data expected 2H 2024.
- SerpinPC registrational PRESent-2 interim analysis planned for 2024; Part 1 data to be shared late 2024/early 2025.
- LB101 (PD-L1xCD47) Phase 1/2a for solid tumors ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000079/0001847903-24-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000079/cnta-20240513.htm
  HTML page:      https://secwatch.observer/filing/0001847903-24-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer